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Abstract
Objective—To determine the plasma triglyceride (TG) and unbound free fatty acid (FFAu) levels 
in infants treated with increasing dosages of soybean lipid, intralipid (IL), infusion.
Study design—TG and FFAu levels were measured in 78 preterm infants (BW 500–2000 g; GA 
23–34 weeks) using the fluorescent probe ADIFAB2 and enzymatic method.
Results—The infants’ BW was 1266.2 ± 440.7 g and GA 28.8 ± 3.1 weeks. TG levels were 77.4 
± 50 mg/dL, 140.2 ± 188 mg/dL (p < .04 compared to levels during low dose IL infusion) and 
135.6 ± 118 mg/dL (p < .004), respectively during increased IL rates. FFAu levels were 17.7 ± 13 
nM, 47.3 ± 102.8 nM (p = .07) and 98 ± 234 nM (p = .03). TG levels correlated with IL dose, the 
rate of IL administration, and FFAu levels. TG and FFAu levels were higher in infants below 28 
weeks’ gestation
Conclusions—Increasing dosage of IL is associated with increasing levels of TG and FFAu, 
especially in infants below 29 weeks of gestation. The increased level of FFAu suggests inefficient 
cellular utilization.
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Introduction
Intravenous fat emulsion is an important part of parenteral nutrition in preterm infants [1,2]. 
The commonly used soybean lipid infusion is intralipid (IL), an emulsion of soy bean oil, 
egg phospholipids and glycerin, usually administered in a 20% concentration [3]. The 
metabolism of IL involves hydrolysis of the triacylglycerols by endothelial lipoprotein 
lipases in the presence of cofactor apolipoprotein C-II, releasing free fatty acids (FFA) and 
glycerides [1]. The FFA are used in liver, heart or skeletal muscles as metabolic fuel or enter 
into adipose tissue to be re-esterified to triglycerides.
The tolerance of lipid infusions is based on the ability to hydrolyze serum triglycerides (TG) 
into FFA. Elevations of TG are used as markers for lipid intolerance and predictors of the 
probability of complications involved with the administration of intralipid [4]. Intralipid 
infusion carries many risks including potential exacerbation of chronic lung disease, 
displacement of bilirubin from albumin, exacerbation of sepsis, thrombocytopenia and 
central nervous system injury [1]. Furthermore, significant elevations of plasma FFA levels 
could result from the lipase-mediated hydrolysis of triglycerides [2]. Lipoprotein lipase 
activity is increased by advancing gestational and postnatal age, and inhibited by stress and 
malnutrition, as seen in the small for gestational age infant [5]. FFA levels reflect the ability 
of the liver to clear and transport them to various organs for their biologic functions. While 
most of the circulating FFA binds to albumin, a small fraction dissociates from albumin as 
the free, unbound molecule (FFAu) [6,7]. Elevation of the latter suggests poor transport of 
FFA to various organ with less nutritional values. To improve our understanding of the 
metabolic process during IL infusion, we examined TG and FFAu levels in preterm infants 
treated with increasing dosage of IL. We hypothesized that increased dose of IL will result in 
increased TG and FFAu levels, the latter a result of inefficient cellular utilization.
Materials and methods
Patients
We measured triglyceride (TG) levels in 78 preterm infants weighing under 2000 g at birth 
as part of a study to assess the effect of intralipid administration on bilirubin metabolism [8]. 
Unbound fatty acid (FFAu) levels were also measured using the fluorescent probe ADIFAB2 
in the plasma samples. Recruitment was carried out in the Neonatal Intensive Care Unit 
(NICU) at Rutgers, Robert Wood Johnson Medical School (RWJMS) and the study was 
approved by the IRBs of Rutgers and the Torrey Pines Institute for Molecular Studies. 
Parental informed consent was obtained and each infant was treated with IL infusion from 1 
to 3 g/kg/d in 1-g/kg/d steps increase during the first week of life. Because the laboratory 
policy is to store all infants blood samples for 7 days it was possible to obtain research 
samples earlier than the age of the infant at consent.
Study design
Plasma TG levels were obtained by the clinicians as part of infant parenteral nutrition 
management with 20% IL administration. The age of IL initiation was 24.0 ± 9.2 hours 
(range 8–55 hours). The number and timing of TG samples and the decision to withhold, 
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reduce or terminate the lipid infusion due to high TG levels were determined by the clinical 
staff and resulted in a range of the number of triglyceride samples and the age at collection 
among the infants. TG level data that was accompanied by information on the dose of 
intralipid and the FFAu levels were utilized for the analysis. The clinical team was unaware 
of FFAu measurement results.
Blood sampling
Plasma samples for TG levels were obtained rarely before IL infusion (IL0) and randomly 
during infusions of 1, 2 and 3 g/kg/day (IL1, IL2, IL3). Samples for FFAu levels were 
obtained from residual samples drawn for clinical indications during those IL dosing 
windows. These samples were collected immediately after completion of the requested 
clinical test, processed and frozen. The deidentified samples were stored at —70 °C and then 
shipped to Fluoresprobe Sciences for determination of FFAu. Of note, serum albumin levels 
were not available for analysis.
TG measurements
An automated enzymatic method was used for the measurement of plasma TG (Roche 
Diagnostics, Florham Park, NY), which included primary hydrolysis of the triglycerides and 
phosphorylation of the resulting glycerol followed by colorimetric detection of the 
enzymatic products.
FFAu measurements
FFAu was measured in the plasma sample using a fluorescently labeled mutant of a fatty 
acid binding protein [9,10]. FFAu concentrations were determined using the ADIFAB2 
probe [10]. Fluorescence was assessed at two emission wavelengths: 457 and 550 nm for the 
FFAu probe (excitation = 375 nm). The ratio of fluorescence at the two wavelengths, 
together with probe characteristics, yielded the FFAu concentrations. Fluorescence was 
measured at 22 °C using a handheld ratio fluorometer in which plasma sample volumes were 
4 mL for FFAu measurements and after dilution the total volume was 200 µL so that FFAu 
was measured at 50 fold dilution of the plasma sample [9,10].
Statistical analysis
The outcome variables (shown as mean ± standard deviation) were treated as continuous, 
normally distributed and examined with the Student t test and chi-square test to document 
TG level differences at different dosages of IL. IL infusion rate was calculated using the IL 
dose and infant weight at time of IL administration. The changes in TG levels as a function 
of increasing dose of IL were analyzed by repeated measures analysis. Correlation analysis 
was performed to evaluate the relationship between TG levels and IL administration rate and 
FFAu concentrations. The analyses were performed with Statistica (StatSoft, Palo Alto, CA); 
p < .05 was considered significant.
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Results
One hundred thirty-three paired TG and FFAu levels were obtained during the first 10 days 
of life in 78 preterm infants with a birth weight of 1266.2 ± 440.7 g and gestational age 28.8 
± 3.1 weeks.
Because the number of samples is small for pre-IL infusion, we compared the changes in TG 
and FFAu when the IL dose was increased from 1 g/kg/24 hours to 2 and 3 g/kg/24 hours. 
As shown in Table 1, TG increased significantly when the IL dose was increased from 1 to 2 
and 3 g/kg/24 hours (p values, .04 and .004), respectively. The FFAu also increased when IL 
dose was increased from 1 to 2 and 3 g/kg/24 hours, (p values, .07 and .03, respectively).
TG levels significantly correlated with IL dose (r = .19), with the rate of IL administration (r 
= .24), as shown in Figure 1, and with FFAu levels (r = .29), as shown in Figure 2. 
Interestingly, FFAu levels did not correlate with the rate of IL infusion.
Table 2 shows that TG levels were higher in infants below 29 weeks’ gestation, with 
significant differences noted at 1 g/kg/24 hours (p = .018) and 2 g/kg/24 hours (p = .009) 
infusions. FFAu levels were higher in these infants (p = .07) during infusions of 2 and 3 
g/kg/24 hours. Among the 25 infants below 29 weeks of gestation (GA-gestational age (BW) 
808.2 ± 224.9 g, GA 25.4 ± 1.7 weeks), 7 (28.0%) had at least one TG level >250 mg/dL, 
compared to 3 (5.7%) of the 53 ≤ 29 weeks (BW 1532.6 ± 289.2 g, GA 30.8 ± 1.7 weeks) (p 
= .01).
Discussion
Preterm infants often cannot be fed adequately via the enteral route and require parenteral 
nutrition to provide the various nutrients and energy. Intravenous lipid emulsions, important 
constituents of parenteral nutrition, provide increased caloric intake and long-chain 
polyunsaturated fatty acids necessary for normal neural development and function. These 
lipids are metabolized by lipoprotein lipases releasing triglycerides and free fatty acids 
which can be used as metabolic fuel in the liver, heart and skeletal muscles or which can 
enter fat cells to be either re-esterified to triglycerides or stored [11]. Most of the FFA in 
serum is bound to albumin but a small portion is unbound [12]. The unbound free fatty acid 
(FFAu) level in adults is 1.5 ± 0.9 nM [13] and in term infants 13.9 ± 3 nM [14].
The inability to effectively clear triglycerides leads to hypertriglyceridemia, which has been 
associated with a number of adverse effects [15], including complication of disorders of 
preterm infants. While the inadvertent overdose of lipid emulsions has resulted in severe 
hypertriglyceridemia causing severe clinical symptoms, the level of safety has been 
suggested to be below 250 mg/dL [16], although different TG concentration norms have also 
been recommended [1]. These ranges are 100–150, < 200, and <250 mg/dL [1]. Several 
reviews have examined the metabolism of triglycerides in intravenous fat infusions [2,17]. 
Morris noted peak TG level was 116.8 ± 60.9 mg/dL, which declined rapidly after the 
cessation of IL. TG levels reflect a combination of endogenous and infused TG, controlled 
by the variability of IL metabolism by individual infants. Thus, that measurement of lipid 
fractions is only useful if the endogenous and infused TG can be separated, measures usually 
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not available to the clinician who has to rely on total TG levels to assess the risk of the lipid 
infusion [18].
The study suffers from the random collection of samples due to the discretion of the 
clinicians, but, in spite of this limitation, we are confident in the results which show that 
increasing dosage of IL is associated with increasing TG and FFAu levels. We have 
demonstrated the relationship between IL dose and FFAu concentrations in previous 
publications [19]. When lipid emulsion is infused, the TG is hydrolyzed by lipoprotein 
lipase via C-II in the endothelial surface to FFA which in turns is taken up by various organs 
for metabolic fuel and to fat tissue to be re-esterified back to TG [20]. If the preterm infants 
had low lipoprotein lipase (LPL) activity, the result will be a high TG but low FFAu levels. 
We speculate that in our study subjects IL dose increase was accompanied by reduced 
metabolic utilization of FFAu resulting in increased FFAu level. The latter could cause a 
dissociation of C-II from LPL inhibiting the hydrolysis accounting for the elevation of TG. It 
appears that the increased dose of IL may not achieve the desired increase in metabolic fuel 
as expected.
It is of interest that the rate of IL infusion correlated with TG levels with a number of infants 
manifesting TG above 250 mg/dL in spite of limiting the infusion rate below 0.15 g/kg/hour, 
which was suggested to be a safe rate [1]. FFAu levels also increased, correlating with TG 
levels, but there was no relationship with FFAu levels and TG when the latter exceeded 250 
mg/dL.
Our findings are consistent with the previous report of the sensitivity of infants below 29 
weeks of gestation to manifesting elevated levels of TG due to IL infusion [21]. The elevated 
FFAu and TG levels suggest a deficiency in the metabolism of IL and question the benefits 
of intravenous fat infusion if the nutritional advantages are absent compared to the potential 
risks.
Our results also demonstrated that FFAu levels in the preterm infants are not predictable and 
often elevated. The potential toxicity of excessive FFAu levels in this population remains to 
be elucidated. In adults, elevated levels of FFAu inhibit T lymphocyte signaling [22]. In a 
previous investigation, we observed that in unstressed newborn rats, FFAu levels decreased 
over the course of the first week of life, while levels in rats exposed to severe hypoxic 
conditions were significantly elevated [23]. The elevated FFAu levels were thought to be due 
to inflammatory mediator caused lipolysis. In another study, we showed that umbilical cord 
FFAu levels were significantly higher in infants with lower Apgar scores with an inverse 
correlation noted between umbilical cord FFAu levels and cord pH [24]. These findings were 
thought to be due to increased serum catecholamine levels during the stressful period or, 
alternately, reduced myocardial uptake of FFA during ischemia [25,26].
The unbound free fatty acid (FFAu) level in adults is 1.5 ± 0.9 nM and in term infants 13.9 
± 3 nM. The high FFAu levels in preterm infants are like and even exceed those in adults 
with a greatly increased risk of death highly correlated with elevated FFAu levels. In the 
TIMI II trial of ST-elevation myocardial infarction, the median FFAu levels in the fourth 
quartile of 1864 patients was 10 nM and these patients had a seven-fold greater risk of death 
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relative to those in the first quartile (median 1.9 nM) [13]. Elevated levels of FFAu may not 
only be associated with neonatal mortality [27] but with increased morbidity since albumin-
bound bilirubin is displaced by FFAu thus increasing the risk bilirubin related neurotoxicity 
[28].
In conclusion, intralipid administration in large doses raises TG and FFAu levels in 
premature infants and increases the risk of potential morbidity and mortality due to bilirubin 
displacement. TG and FFAu levels are unpredictable and thus require monitoring during 
intralipid administration. However, the utility of intralipid administration to provide calories 
needs to be addressed in infants who demonstrate intolerance to the infusion.
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Figure 1. 
The rate of intralipid administration and triglyceride levels. Figure 1 demonstrates rate of 
Intralipid administration from 0.02 to 0.15 g/kg/hour and serum triglyceride levels from 20 
to 450 mg/dL. (r = .24, p < .05).
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Figure 2. 
Unbound free fatty acid levels (below 200 nM) and triglyceride levels. Figure 2 shows the 
relationship between FFAu and triglyceride (TG) levels (r = .29, p < .05).
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Table 2.
TG and FFAu Levels with reference to gestational age.
IL dose g/kg/24 h Triglyceride, mg/dL FFAu, nM
<29 wks ≥29 wks  p <29 wks ≥29 wks p
0 57 ± 21 n= 3 97 ± 8 n= 2 .09  14.4 ± 3 n= 3 9.5 ± 3 n= 2 .18
1 97.1 ± 64 n= 19 61.1 ± 26 n= 23 .018  18.7 ± 14 n= 19 16.8 ± 11 n= 23 .63
2 227.9 ± 265 n= 17 75.3 ± 30 n= 23 .009 80.2 ± 152 n= 17 21.8 ± 11 n= 23 .07
3 160.6 ± 128 n= 19 118 ± 128 n= 27 .23  172 ± 332 n= 19 45.7 ± 109 n= 27 .07
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